Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center
Authors' conclusion
This juvenile localized scleroderma cohort is one of the largest reported from a single center and demonstrated an increase in the use of systemic therapy following the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012.
Study context
- Population
- Pediatric juvenile localized scleroderma patients with ≥ 3 years of follow-up, 1999–2020, single tertiary care pediatric hospital, USA
- Participants
- 101 participants
- Exposure
- Systemic vs topical therapy; treatment trends before vs after the 2012 CARRA consensus treatment plan
- Systemic therapyn = 63
- Topical therapyn = 38reference
- Outcome
- Treatment trends starting in 2013 vs before
Methodological detailssingle-centre, tertiary care
- Single-centre
- Tertiary care
Main finding
As reported in the abstract
- Treated in combined rheumatology-dermatology program, starting in 2013 vs before: 47% vs. 20%, p = 0.008
- Received systemic therapy, starting in 2013 vs before: 78% vs. 55%, p < 0.05
Observational data: associations, not effects.
Further findings
Treatment setting by therapy
- Systemic therapy: combined rheumatology-dermatology program
- 67%
- Systemic therapy: rheumatology clinic
- 30%
- Topical therapy: dermatology clinic
- 71%
Original publication
Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center. Pediatr Rheumatol Online J. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →